A patient with rheumatoid arthritis who had a normal delivery under etanercept treatment.

In recent years, biologics have been widely administered for treating rheumatoid arthritis (RA): however, the safety of these drugs has not been adequately established in embryos and fetuses. We report the case of a pregnant RA patient treated with etanercept, an anti-tumor necrosis factor (TNF) agent. She continued to receive etanercept treatment after becoming pregnant without any complications, finally giving successful birth to a baby girl at 39 weeks. This suggests that etanercept may be selected to treat RA patients with active arthritis who desire pregnancy with lower risks.